Posters & Publications

Date	Title	View
May 23, 2019	I-O 2019 <b>World Congress Phase 1 results for NLG802</b>	Add Files I-O 2019 World Congress Phase 1 results for NLG802 235.6 KB
Apr 2, 2019	AACR 2019 <b>Phase 2 Results for NLG207 Plus Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</b>	Add Files NLG207 2019 AACR Poster 447.1 KB
Dec 2, 2018	ASH 2018 <strong>Updated Phase 1 Data of Indoximod Plus Standard Induction Chemotherapy in Newly Diagnosed AML </strong>	Add Files ASH 2018 Updated Phase 1 Data of Indoximod Plus Standard Induction Chemotherapy in Newly Diagnosed AML 909.1 KB
Nov 9, 2018	SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Metastatic Pancreatic Cancer</strong>	Add Files SITC 2018 Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Metastatic Pancreatic Cancer 4.3 MB
Nov 9, 2018	SITC 2018 <strong>Phase 1 Pharmacokinetic Data for NLG802 Prodrug</strong>	Add Files SITC 2018 Phase 1 Pharmacokinetic Data for NLG802 Prodrug 158.4 KB
Nov 9, 2018	SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Advanced Melanoma</strong>	Add Files SITC 2018 Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Advanced Melanoma 4.3 MB
Jul 1, 2018	ISPNO 2018 <strong>Updated Phase 1 Data for Indoximod Plus Radio-Immunotherapy for Pediatric Patients with Newly Diagnosed DIPG</strong>	Add Files ISPNO 2018 Updated Phase 1 Data for Indoximod Plus Radio-Immunotherapy for Pediatric Patients with Newly Diagnosed DIPG 1.5 MB
Jun 4, 2018	ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Pembrolizumab in Advanced Melanoma</strong>	Add Files ASCO 2018 Phase 2 Results for Indoximod Plus Pembrolizumab in Advanced Melanoma 4.2 MB
Jun 3, 2018	ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Gemcitabine/nab-Paclitaxel in Metastatic Pancreatic Cancer</strong>	Add Files ASCO_2018_Phase_2_Results_for_Indoximod_Plus_Gemcitabine_nab_Paclitaxel_in_Metastatic_Pancreatic_Cancer.pdf 4.3 MB
Apr 17, 2018	AACR 2018 <strong>Indoximod Modulates AhR-driven Transcription of Genes That Control Immune Function</strong>	Add Files AACR 2018 Indoximod Modulates AhR-driven Transcription of Genes That Control Immune Function 4.2 MB
Apr 15, 2018	AACR 2018 <strong>Phase 1 Study of Indoximod Plus Radiation & Chemotherapy for Pediatric Patients with DIPG and Other Brain Tumors</strong>	Add Files AACR 2018 Phase 1 Study of Indoximod Plus Radiation & Chemotherapy for Pediatric Patients with DIPG and Other Brain Tumors 2.4 MB
Nov 20, 2017	SNO 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong>	Add Files SNO 2017 Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer 1 MB
Nov 10, 2017	TCH 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong>	Add Files TCH 2017 Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer 3.6 MB
Sep 2, 2017	CIC 2017 <strong>Interim Phase 2 of Indoximod plus Pembrolizumab in Advanced Melanoma</strong>	Add Files View Presentation 2.1 MB
Jun 22, 2017	EHA 2017 <strong>Phase I Indoximod plus Idarubicin & Cytarabine for Newly Diagnosed Acute Myeloid Leukemia</strong>	Add Files EHA 2017 Phase I Indoximod plus Idarubicin & Cytarabine for Newly Diagnosed Acute Myeloid Leukemia 893.9 KB
Jun 5, 2017	ASCO 2017 <strong>Phase II Double-blind study of Metastatic Castration-resistant Prostate Cancer</strong>	Add Files ASCO 2017 Phase II Double-blind study of Metastatic Castration-resistant Prostate Cancer 331.2 KB
Apr 4, 2017	AACR Plenary 2017 <strong>Indoximod plus Keytruda (pembrolizumab) Phase II Interim in Advanced Melanoma</strong>	Add Files AACR Plenary 2017 Indoximod plus Keytruda (pembrolizumab) Phase II Interim in Advanced Melanoma 907 KB
Apr 4, 2017	AACR 2017 <strong>NLG802 Prodrug Poster Presentation</strong>	Add Files AACR 2017 NLG802 Prodrug Poster Presentation 2.7 MB
Nov 22, 2016	SNO 2016 <strong>Indoximod + Temozolomide Brain Tumor Trial</strong>	Add Files SNO 2016 Indoximod + Temozolomide Brain Tumor Trial 413.5 KB
Jun 5, 2016	ASCO 2016 <strong>Pancreas indoximod</strong>	Add Files ASCO 2016 Pancreas indoximod 843.2 KB
Jun 5, 2016	ASCO 2016 <strong>Melanoma indoximod</strong>	Add Files ASCO 2016 Melanoma indoximod 1.3 MB
Apr 20, 2016	ASCO GI 2016 <strong>Indoleamine Phase II Trial</strong>	Add Files ASCO GI 2016 Indoleamine Phase II Trial 561.8 KB
Jan 22, 2016	ASCO GI <strong>Indoximod + Gemcitabine/nab-Paclitaxel</strong>	Add Files ASCO GI Indoximod + Gemcitabine/nab-Paclitaxel 448.3 KB
Dec 15, 2015	SABCS 2015 <strong>Indoximod Phase II Metastatic Breast Cancer Trial</strong>	Add Files SABCS 2015 Indoximod Phase II Metastatic Breast Cancer Trial 301.6 KB
Nov 6, 2015	SITC 2015 <strong>GDC-0919 + PD-L1</strong>	Add Files SITC 2015 GDC-0919 + PD-L1 2.6 MB
Oct 20, 2015	ECCO-ESMO 2015 <strong>Indoximod + Ipilimumab Melanoma Trial</strong>	Add Files ECCO-ESMO 2015 Indoximod + Ipilimumab Melanoma Trial 414.7 KB
Sep 29, 2015	ESMO 2015 <strong>GDC-0919</strong>	Add Files ESMO 2015 GDC-0919 1.7 MB
Jun 1, 2015	ASCO 2015 <strong>Indoximod and Temozolomide</strong>	Add Files ASCO 2015 Indoximod and Temozolomide 144 KB
Jul 28, 2014	IUMS <strong>Highly efficacious influenza vaccination using HyperAcute® Technology</strong>	Add Files IUMS Highly efficacious influenza vaccination using HyperAcute® Technology 1.3 MB
Jun 2, 2014	ASCO 2014 <strong>Algenpantucel-L</strong>	Add Files ASCO 2014 Algenpantucel-L 585.5 KB
Jun 2, 2014	ASCO 2014 <strong>Sipuleucel-T +- Indoximod</strong>	Add Files ASCO 2014 Sipuleucel-T +- Indoximod 575.1 KB
Jun 1, 2014	ASCO 2014 <strong>Tergenpumatucel-L vs. Docetaxel</strong>	Add Files ASCO 2014 Tergenpumatucel-L vs. Docetaxel 1.1 MB
Jun 1, 2014	ASCO 2014 <strong>Docetaxel + Indoximod</strong>	Add Files ASCO 2014 Docetaxel + Indoximod 1.3 MB
Jun 1, 2014	ASCO 2014 <strong>Ad.p53 + Indoximod</strong>	Add Files ASCO 2014 Ad.p53 + Indoximod 1.1 MB
Jun 1, 2014	ASCO 2014 <strong>NLG919</strong>	Add Files ASCO 2014 NLG919 1 MB

Posters & Publications

I-O 2019 <b>World Congress Phase 1 results for NLG802</b>

AACR 2019 <b>Phase 2 Results for NLG207 Plus Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</b>

ASH 2018 <strong>Updated Phase 1 Data of Indoximod Plus Standard Induction Chemotherapy in Newly Diagnosed AML </strong>

SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Metastatic Pancreatic Cancer</strong>

SITC 2018 <strong>Phase 1 Pharmacokinetic Data for NLG802 Prodrug</strong>

SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Advanced Melanoma</strong>

ISPNO 2018 <strong>Updated Phase 1 Data for Indoximod Plus Radio-Immunotherapy for Pediatric Patients with Newly Diagnosed DIPG</strong>

ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Pembrolizumab in Advanced Melanoma</strong>

ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Gemcitabine/nab-Paclitaxel in Metastatic Pancreatic Cancer</strong>

AACR 2018 <strong>Indoximod Modulates AhR-driven Transcription of Genes That Control Immune Function</strong>

AACR 2018 <strong>Phase 1 Study of Indoximod Plus Radiation & Chemotherapy for Pediatric Patients with DIPG and Other Brain Tumors</strong>

SNO 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong>

TCH 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong>

CIC 2017 <strong>Interim Phase 2 of Indoximod plus Pembrolizumab in Advanced Melanoma</strong>

EHA 2017 <strong>Phase I Indoximod plus Idarubicin &amp; Cytarabine for Newly Diagnosed Acute Myeloid Leukemia</strong>

ASCO 2017 <strong>Phase II Double-blind study of Metastatic Castration-resistant Prostate Cancer</strong>

AACR Plenary 2017 <strong>Indoximod plus Keytruda (pembrolizumab) Phase II Interim in Advanced Melanoma</strong>

AACR 2017 <strong>NLG802 Prodrug Poster Presentation</strong>

SNO 2016 <strong>Indoximod + Temozolomide Brain Tumor Trial</strong>

ASCO 2016 <strong>Pancreas indoximod</strong>

ASCO 2016 <strong>Melanoma indoximod</strong>

ASCO GI 2016 <strong>Indoleamine Phase II Trial</strong>

ASCO GI <strong>Indoximod + Gemcitabine/nab-Paclitaxel</strong>

SABCS 2015 <strong>Indoximod Phase II Metastatic Breast Cancer Trial</strong>

SITC 2015 <strong>GDC-0919 + PD-L1</strong>

ECCO-ESMO 2015 <strong>Indoximod + Ipilimumab Melanoma Trial</strong>

ESMO 2015 <strong>GDC-0919</strong>

ASCO 2015 <strong>Indoximod and Temozolomide</strong>

IUMS <strong>Highly efficacious influenza vaccination using HyperAcute® Technology</strong>

ASCO 2014 <strong>Algenpantucel-L</strong>

ASCO 2014 <strong>Sipuleucel-T +- Indoximod</strong>

ASCO 2014 <strong>Tergenpumatucel-L vs. Docetaxel</strong>

ASCO 2014 <strong>Docetaxel + Indoximod</strong>

ASCO 2014 <strong>Ad.p53 + Indoximod</strong>

ASCO 2014 <strong>NLG919</strong>

EHA 2017 <strong>Phase I Indoximod plus Idarubicin & Cytarabine for Newly Diagnosed Acute Myeloid Leukemia</strong>